Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 219

Sort by

Sort Order Select

Journal Articles

Impact of Infectious Complications Should be Considered When Choosing Chemotherapy for Elderly Acute Myeloid Leukemia Fit Patients: Results of a Large Monocentric Retrospective Study

Erika Borlenghi, Erika Borlenghi, Irene Terrenato, Margherita Oberti, Giulia Soverini, Angelica Spolzino, Elisa Cerqui, Simone Maifredi, Ester Lovato, Lorenzo Masina, Francesca Federico, Diego Bertoli, Francesco Marchesi, Giuseppe Rossi, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 5946.

https://doi.org/10.1182/blood-2024-203868

Published: 2024

Journal Articles

Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2024) 144 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2024-202530

Published: 2024

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2023) 142 (Supplement 1): 956.

https://doi.org/10.1182/blood-2023-180568

Published: 2023

Journal Articles

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, Massimo Bernardi, Nicola Fracchiolla, Federica Gigli, Claudia Basilico, Lorenzo Masina, Erika Borlenghi, Alessandro Bruno, Giselda Gela, Diego Bertoli, Giuseppe Rossi, Alessandra Tucci, Federico Lussana, Elisabetta Todisco

Blood (2023) 142 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2023-181212

Published: 2023

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Blood (2022) 140 (Supplement 1): 9399–9401.

https://doi.org/10.1182/blood-2022-156576

Published: 2022

Journal Articles

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Blood (2022) 140 (Supplement 1): 1814–1816.

https://doi.org/10.1182/blood-2022-162178

Published: 2022

Journal Articles

Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy

Angelo Belotti, Rossella Ribolla, Claudia Crippa, Marco Chiarini, Viviana Giustini, Samantha Ferrari, Annalisa Peli, Chiara Cattaneo, Aldo Roccaro, Barbara Frittoli, Marta Salis, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci

Blood (2022) 140 (Supplement 1): 1140–1141.

https://doi.org/10.1182/blood-2022-157520

Published: 2022

Journal Articles

Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Pilar Martínez Sánchez, Paul Gordon, Stefan Schwartz, Giuseppe Rossi, Francoise Huguet, Jesus Maria Hernández-Rivas, Priti Kadu, Hansen L. Wong, Ana Markovic, Yuliya Katlinskaya, Bharat Panwar, Gerhard Zugmaier

Blood (2021) 138 (Supplement 1): 2303.

https://doi.org/10.1182/blood-2021-150018

Published: 2021

Journal Articles

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Giuseppe Rossi, Henry Miles Prince, Constantine S. Tam, Matthew Ku, Catherine Thieblemont, Leslie L. Popplewell, Martin Wermke, Corinne Haioun, Nicole Wong Doo, Andreas Viardot, Andrés J M Ferreri, Silvia Ferrari, Hansen L. Wong, Priti Kadu, Gerhard Zugmaier, Yi Zeng, Alessandro Rambaldi

Blood (2021) 138 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2021-152822

Published: 2021

Journal Articles

Adverse Prognostic Role of IDH2 Mutations at Diagnosis and during Follow-up in Patients with Acute Myeloid Leukemia and Normal Karyotype

Erika Borlenghi, Diego Bertoli, Chiara Cattaneo, Margherita Sciumé, Elisa Cerqui, Chiara Pagani, Nicola Bianchetti, Margherita Oberti, Rossella Leopaldo, Cecilia Carbone, Silvana Archetti, Giuseppe Rossi, Alessandra Tucci

Blood (2021) 138 (Supplement 1): 2366.

https://doi.org/10.1182/blood-2021-149719

Published: 2021

Journal Articles

Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a European retrospective study)

Chiara Pagani, Chiara Rusconi, Alessia Dalla Pria, Emanuele Ravano, Philipp Schommers, Mariana Bastos-Oreiro, Luisa Verga, Guido Gini, Michele Spina, Luca Arcaini, Sara Steffanoni, Davide Dalu, Chiara Cattaneo, Fabio Facchetti, Giuseppe Rossi, Alessandra Tucci, Alessandro Re

Blood (2021) 138 (Supplement 1): 2506.

https://doi.org/10.1182/blood-2021-151149

Published: 2021

Journal Articles

A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 2496.

https://doi.org/10.1182/blood-2021-149649

Published: 2021

Journal Articles

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Blood (2021) 138 (Supplement 1): 1262.

https://doi.org/10.1182/blood-2021-153028

Published: 2021

Journal Articles

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Angelo Belotti, Rossella Ribolla, Alberta Villanacci, Marco Chiarini, Viviana Giustini, Giulia Vittoria Facchetti, Claudia Crippa, Valeria Cancelli, Samantha Ferrari, Annalisa Peli, Chiara Bottelli, Chiara Cattaneo, Chiara Saeli, Aldo M. Roccaro, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci

Blood (2021) 138 (Supplement 1): 1641.

https://doi.org/10.1182/blood-2021-147694

Published: 2021

Journal Articles

Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin

Chiara Cattaneo, Francesco Marchesi, Valentina Bonuomo, Nicola S Fracchiolla, Anna Candoni, Marianna Criscuolo, Lucia Prezioso, Crescenza Pasciolla, Maria Ilaria Del Principe, Michelina Dargenio, Giuseppe Tarantini, Maria Enza Mitra, Francesca Farina, Federica Colnaghi, Mariarita Sciumè, Gianpaolo Nadali, Alessandro Busca, Giuseppe Rossi, Livio Pagano

Blood (2021) 138 (Supplement 1): 4381.

https://doi.org/10.1182/blood-2021-149080

Published: 2021

Journal Articles

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Blood (2021) 138 (18): 1705–1720.

https://doi.org/10.1182/blood.2020010572

Published: 2021

Includes: Supplemental data

Journal Articles

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Blood (2021) 137 (18): 2495–2508.

https://doi.org/10.1182/blood.2020008414

Published: 2021

Includes: Supplemental data

Journal Articles

External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry

Angelo Belotti, Rossella Ribolla, MD, Valeria Cancelli, MD, Alberta Villanacci, Valentina Angelini, Samantha Ferrari, Annalisa Peli, MD, Chiara Cattaneo, MD, Marco Chiarini, MSc, Luigi Grazioli, MD, Giuseppe Rossi, MD, Alessandra Tucci, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-135969

Published: 2020

Journal Articles

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 3–5.

https://doi.org/10.1182/blood-2020-134398

Published: 2020

NARROW

Impact of Infectious Complications Should be Considered When Choosing Chemotherapy for Elderly Acute Myeloid Leukemia Fit Patients: Results of a Large Monocentric Retrospective Study

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy

Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Adverse Prognostic Role of IDH2 Mutations at Diagnosis and during Follow-up in Patients with Acute Myeloid Leukemia and Normal Karyotype

Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a European retrospective study)

A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Posaconazole at Standard Dose Is Safe and More Effective Than Echinocandins As IFD Prophylaxis in Patients with FLT3 Mutated AML Treated with Midostaurin

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only